Tirzepatide, as a dual GIP/GLP-1 agonist, may produce slightly more pronounced effects because it typically produces greater weight loss (15% to 20% of body weight versus 10% to 15% for pure GLP-1 agonists) and more dramatic metabolic improvements
Antipova T, Sapozhnikova D, Liu B, Seredenin S
Cha c nh gi no.
The medications unique molecular structure allows it to remain active in the bloodstream for approximately one week, making it convenient for patients who prefer weekly rather than daily injections
But researchers who are also taking insulin, sulfonylureas, or other glucose-lowering agents face meaningful hypoglycemia risk
I continued to rush to the toilet multiple times that day, and it took three days for the nausea to fully subside